27 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
by multiplying the percentage of cells (0 to 100%) with intensity of Cyclin E1 expression (0 to 3); Liu JF., et al. Journal of Clinical Oncology 41 … calculated by multiplying the percentage of cells (0 to 100%) with intensity of Cyclin E1 expression (0 to 3). Harismendy, et al. Presented at the AACR
8-K
EX-99.2
ZNTL
Zentalis Pharmaceuticals Inc
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
by multiplying the percentage of cells (0 to 100%) with intensity of Cyclin E1 expression (0 to 3). Harismendy, et al. Presented at the AACR Special … %) with intensity of Cyclin E1 expression (0 to 3); Liu JF., et al. Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 5513-5513; Abbreviations: CI
8-K
EX-99.1
3gxsi9
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
wcskgz42xc4nnvgaw
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.2
5t5lvh
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.3
t36d6tddxqwc
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
t3l5u08 vf
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.2
r807sp6
8 Apr 22
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
5:05pm
8-K
EX-99.2
n987qca1jb2b7 x84i
28 Jun 21
Other Events
7:11am
10-K
ydpg29kj ptw2xtbajb7
25 Mar 21
Annual report
7:17am
424B4
7p15 4icm9
31 Jul 20
Prospectus supplement with pricing info
12:00am